Icecure Medical Ltd Ordinary Shares ICCM 深 沪
等待开盘 09-17 09:30:00 美东时间
1.02
-0.060
-5.56%
华盛通- 最 高1.08
- 今 开1.08
- 成交量 162.69万股
- 最 低 1.02
- 昨 收 1.08
- 总市值 6101.76万
- 52周最高 1.6288
- 市盈率 静 --
- 换手率 2.72%
- 52周最低 0.471
- 委 比 48.46%
- 总股本 5982.12万
- 历史最高 12.167
- 量 比 1.08
- 振 幅 5.56%
- 历史最低 0.471
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
今天 00:29
IceCure Medical Gains Shareholder Approval at Annual Meeting
An update from Icecure Medical ( ($ICCM) ) is now available. On August 20, 2025...
08-21 05:30
HC Wainwright & Co. Maintains Buy on Icecure Medical, Lowers Price Target to $2
HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from $2.5 to $2.
08-15 19:39
Icecure Medical Q2 EPS $(0.06) Beats $(0.07) Estimate, Sales $525.000K Miss $662.500K Estimate
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 7.69 percent. This is unchanged from the same period last year. The company reported
08-13 20:32
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Examining the Future: Icecure Medical's Earnings Outlook
Icecure Medical (NASDAQ:ICCM) is gearing up to announce its quarterly earnings ...
08-13 03:01
IceCure Medical Completes $10M Rights Offering To Support Tumor-Freezing Technology Expansion
IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor
07-29 21:14
IceCure Medical ProSense Featured At Japanese Breast Cancer Society Conference
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over
07-25 21:03
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
CAESAREA, Israel, July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology t...
07-24 21:00
